Your Shingles Shot May Be Quietly Protecting Your Brain Too

A Vaccine With an Unexpected Bonus

Most people who get the shingles vaccine are thinking about one thing: avoiding the notoriously painful, blistering rash. But a rapidly growing body of research is pointing to a remarkable secondary benefit — the shot may also help shield the aging brain from dementia. The shingles vaccine may significantly help protect older adults against dementia, a growing body of evidence shows. Scientists are still working to understand exactly why, but the clues are pointing straight at the nervous system.

Shingles, triggered by the reactivation of the varicella-zoster virus in the body, can cause a "war zone" of inflammation in the brain, according to Dr. Jennifer Pauldurai, medical director of the Inova Brain Health and Memory Disorders Program in Northern Virginia. Most people were infected with the virus that causes chickenpox as children. The virus then lies dormant in nerve roots for decades. As we age and our immune systems weaken, it can reactivate, causing the painful skin blisters of shingles. About 1 million people in the U.S. develop shingles annually.

What the Numbers Are Showing

New research published in the Annals of Internal Medicine suggests that shingles vaccination may be associated with a reduced risk of dementia among older adults entering skilled nursing facilities. The observational study included claims and electronic health record data from over 500,000 Medicare beneficiaries with a mean age of 79. Receipt of at least one dose of the vaccine within 12 months of admission was associated with a 24% lower relative risk for dementia compared with no vaccination.

Earlier research adds further weight to the connection. The recombinant vaccine is associated with a significantly lower risk of dementia in the six years post-vaccination — specifically, receiving it is associated with a 17% increase in diagnosis-free time, translating into 164 additional days lived without a diagnosis of dementia in those subsequently affected. A landmark natural experiment out of Wales, which exploited a quirk in vaccine eligibility based on birth dates to eliminate confounding factors, estimated that vaccinees were 20% less likely to develop dementia in the next seven years.

Why the Vaccine Might Work on the Brain

While the exact biological mechanism remains unclear, one suggestion is that preventing shingles and reducing viral reactivation may help protect the brain from inflammation or other neurological effects associated with the varicella-zoster virus. The chickenpox virus has been linked to an increased risk of heart disease and stroke — both risk factors for dementia. Some research suggests the virus may also damage the lining of blood vessels, including those in the brain, or damage nerve cells directly. Infections may also increase brain inflammation, which may play a role in dementia onset.

Another hypothesis focuses on the vaccine's immune-stimulating properties. Some research suggests that components known as adjuvants, which enhance immune responses, could play a role in promoting protective effects beyond infection prevention. Taken together, the findings strongly implicate VZV reactivation as a modifiable risk factor for dementia. Some doctors are already putting this knowledge to practical use. One physician described adding the brain-protection angle to his standard pitch for the vaccine, noting that shingles is "probably the most painful rash imaginable" — and that there is now some evidence it may also help protect your brain.

What This Means for You

The shingles vaccine, recommended for people 50 and older, is highly effective in preventing or limiting virus reactivation and subsequent shingles outbreaks. The vaccine may significantly reduce the risk of developing dementia, and may also have a protective effect for those already diagnosed with dementia, potentially slowing the progress of the disease. Researchers caution that more work is needed before any definitive conclusions can be drawn. As one UCLA geriatrics professor put it, "The takeaway from this research is 'stay tuned.'"

Still, the convergence of evidence from multiple large studies across different countries and populations is hard to ignore. A nationwide randomized study is now underway investigating whether vaccination against shingles can reduce the risk of cardiovascular disease and dementia in older adults — a trial that could finally move this connection from compelling correlation to confirmed cause and effect. For now, the case for getting vaccinated against shingles has never looked stronger.